Lebrikizumab for Moderate to Severe Atopic Dermatitis in Patients Age ≥60 Years

Atopic dermatitis (AD) significantly impacts adults, with a meta-analysis showing that 26.1% of AD cases have an onset after age 16 years, according to a poster presented at the Revolutionizing Atopic Dermatitis (RAD) June 2024 meeting. Lebrikizumab, a monoclonal antibody targeting IL-13, a key cytokine in AD, was analyzed for efficacy and safety in adults aged 60 years and older with moderate to severe AD.

This analysis pooled data from 2 Phase 3 trials, ADvocate1 and ADvocate2, involving 98 patients aged 60 years and older (28 on placebo and 70 on lebrikizumab). Patients received lebrikizumab 250 mg bi-weekly or placebo for 16 weeks. Baseline demographics, including age, sex, race, and AD severity, were comparable between groups, with the mean age being 67.2 years for the lebrikizumab group and 69 years for the placebo group.

Efficacy was assessed at week 16 using several measures: Investigator’s Global Assessment (IGA) score of 0/1 with at least a 2-point improvement, ≥75% improvement in the Eczema Area and Severity Index (EASI-75), change from baseline in EASI percentage, and a ≥4-point improvement in the Pruritus Numeric Rating Scale (NRS). Statistical analyses included Cochran Mantel Haenszel tests for categorical outcomes and analysis of covariance models for continuous outcomes.

Results showed that 34.5% of patients treated with lebrikizumab achieved an IGA score of 0/1 compared to 11% of those on placebo (P=0.022). EASI-75 was achieved by 48.9% of lebrikizumab-treated patients vs 16.3% on placebo (P=0.004). Additionally, 45.5% of lebrikizumab patients reported a ≥4-point improvement in pruritus NRS, compared to 12.2% on placebo (P=0.004). The mean percent change from baseline in EASI was significantly greater in the lebrikizumab group (-58.5%) compared to the placebo group (-29.4%) (P=0.002).

Safety outcomes for lebrikizumab were consistent with the overall modified safety population, indicating no new safety concerns. These findings suggest that lebrikizumab is an effective and safe treatment option for older adults with moderate to severe AD.

Reference

Armstrong A, Agell H, Atwater AR, Chen S, et al. Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age. Poster presented at: Revolutionizing Atopic Dermatitis; June 8-10, 2024; Chicago, IL.